🔎 Trials Near Me

Utama › Limfoma Sel B Besar Difus › Minnesota

Kajian klinikal Limfoma Sel B Besar Difus di Minnesota

16 kajian untuk Limfoma Sel B Besar Difus sedang mencari peserta di lokasi di Minnesota.

Bandar di Minnesota

Teks kajian rasmi (Bahasa Inggeris)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • University of Minnesota Medical Center, Minneapolis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06500273

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06834373

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • dan 3 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06649812

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Mayo Clinic Rochester, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03418038

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Mayo Clinic - Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  • University of Minnesota/Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT06536049

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Rochester
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Mayo Clinic Rochester, Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

Auto Stem Cell Transplant for Lymphoma Patients

  • Masonic Cancer Center, University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Sehingga umur 75 · Semua jantina · Dikemas kini 4 Nov 2025 · NCT03125642

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • Essentia Health Hibbing Clinic, Hibbing
  • dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Okt 2025 · NCT05890352

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Sep 2024 · NCT06238648

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.